Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28388489 | 0.90 | CMA1 (0.48) | ELANEMAPK1ACEF2 | |
| SCHEMBL23863881 | 0.90 | CMA1 (0.48) | ELANEMAPK1ACEF2 | |
| SCHEMBL16706532 | 0.90 | CMA1 (0.48) | ELANEMAPK1ACEF2 | |
| SCHEMBL18094969 | 0.90 | OPRM1 (0.45) | ELANEACE2ACEF2 | |
| SCHEMBL16703185 | 0.90 | OPRM1 (0.45) | ELANEACE2ACEF2 | |
| SCHEMBL16703282 | 0.89 | DPP4 (0.50) | ELANESMN1; SMN2MAPK1ACEDPP4 | |
| SCHEMBL29613674 | 0.89 | DPP4 (0.50) | ELANESMN1; SMN2MAPK1ACEDPP4 | |
| SCHEMBL20859018 | 0.89 | DPP4 (0.50) | ELANESMN1; SMN2MAPK1ACEDPP4 | |
| SCHEMBL16703281 | 0.89 | DPP4 (0.50) | ELANESMN1; SMN2MAPK1ACEDPP4 | |
| SCHEMBL19603004 | 0.89 | DPP4 (0.50) | ELANESMN1; SMN2MAPK1ACEDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| EP-3564234-A1 | NMDA ANTAGONIST PRODRUGS | AstraZeneca AB (SE) | 2019-11-06 | — | — | EP | disclosed |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-05-23 | — | — | US | disclosed |
| EP-3066091-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-10207994-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2019-02-19 | — | — | US | disclosed |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2018-02-08 | — | — | US | disclosed |
| US-9822075-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| EP-3066091-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067923-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885SMN1; SMN2 1666/4885MAPK1 1508/4885 |
| US-10815199-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885SMN1; SMN2 1666/4885MAPK1 1508/4885 |
| US-10207994-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885SMN1; SMN2 1666/4885MAPK1 1508/4885 |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885SMN1; SMN2 1666/4885MAPK1 1508/4885 |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885SMN1; SMN2 1666/4885MAPK1 1508/4885 |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885SMN1; SMN2 1666/4885MAPK1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.